A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
← catalyst calendarNCT05768386 · readout ≤ 4,913 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
172estimated
Sites
41
Countries
Australia, Belgium, Brazil +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-01 | actual | When the study began enrolling |
| Primary completion | Jan 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A
Primary outcome
what the primary-completion date above is the date OFEvaluate the long-term safety of BMN 270
measured Duration of study (10 years)
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed